MONOFERRIC
Total Payments
$3.3M
Transactions
12,863
Doctors
6,252
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.4M | 4,806 | 3,043 |
| 2023 | $1.1M | 4,934 | 2,932 |
| 2022 | $762,878 | 3,123 | 1,875 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $1.3M | 431 | 40.2% |
| Travel and Lodging | $820,268 | 1,100 | 25.2% |
| Consulting Fee | $745,379 | 103 | 22.9% |
| Food and Beverage | $377,662 | 11,213 | 11.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,613 | 7 | 0.1% |
| Education | $321.39 | 9 | 0.0% |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.3M
- Total Doctors 6,252
- Transactions 12,863
About MONOFERRIC
MONOFERRIC is a drug associated with $3.3M in payments to 6,252 healthcare providers, recorded across 12,863 transactions in the CMS Open Payments database. The primary manufacturer is Pharmacosmos Therapeutics Inc..
Payment data is available from 2022 to 2024. In 2024, $1.4M was paid across 4,806 transactions to 3,043 doctors.
The most common payment nature for MONOFERRIC is "Honoraria" ($1.3M, 40.2% of total).